Navigation Links
Informed Medical Communications Takes the Lead in Response to FDA's 'Bad Ad Program'
Date:5/25/2010

EDISON, N.J., May 25 /PRNewswire/ -- Informed Medical Communications (IMC), a leading full-service provider of peer-to-peer medical forums and integrated medical communications for the bio-pharmaceutical industry, today announced its "Commitment to Compliance" initiative, responding to the FDA's new program to minimize misleading drug advertising and promotion.  Recognizing the level of complexity the FDA's "Bad Ad Program" adds to pharmaceutical marketing, IMC issued a series of industry communications to reinforce its position on compliant dissemination of pharmaceutical product information.  Additionally, IMC began a multi-faceted campaign to inform the industry regarding its longstanding compliance training policy for its elite team of Medical Moderators and other staff responsible for communications with healthcare professionals.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080512/NYM105LOGO )

Steve Budd, IMC's CEO commented, "We're finding that with growing levels of compliance uncertainty in the market, our clients, now more than ever, are valuing the unique role and rigorous training of our Medical Moderators.  I believe our 25 years without compliance violations is a testament to the strong role our Moderators play in ensuring compliance during peer-to-peer events."  With growing challenges facing pharmaceutical marketers, IMC hopes the initiative will provide pharmaceutical customers with added comfort regarding IMC's low-risk, high-impact services for meeting brand objectives.  As Jaime Nguyen, MD, IMC's Compliance Officer summarizes, "IMC's Moderated format for driving deep peer discussion mitigates risk for our clients and enables physicians to engage in germane dialogue on information and data that is on-label, current, and truthful."

About Informed Medical Communications

Informed Medical Communications (www.informedmedical.com), headquartered in Edison, NJ, is an interactive medical marketing group of companies providing services to the biopharmaceutical industry. The companies include The Peer Group and RxDialogue, industry innovators and leaders in conducting general and specialty peer-to-peer medical programs, respectively.  Additionally, IMC's major businesses are enhanced by MRxHealth, the market research and consulting infrastructure that supports IMC's ongoing development and effectiveness of non-traditional marketing programs for biopharmaceutical clients, and Dialogue Training, a communications training service for elite skill development in three areas: (1) leadership, (2) sales, and (3) training/facilitation.  The IMC network of companies delivers integrated marketing programs for pharmaceutical marketers, with the goal of improving the dialogue among healthcare practitioners in understanding health conditions and their medical options. IMC is a private-equity backed, privately held company.


'/>"/>
SOURCE Informed Medical Communications
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
(Date:2/24/2017)... , Feb. 23, 2017  The particle ... million by 2021 from USD 275.9 million in ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... spending on pharmaceutical R&D, and growth in manufacturing ... the market growth for particle counters. On the ...
(Date:2/23/2017)... 23, 2017 Visiomed, the French leader ... 1997, is changing the landscape of healthcare with ... with pro-active, custom-made solutions. Recognizing the rising demand ... affordable healthcare without walls, Visiomed has launched BewellConnect, ... with healthcare professionals that is empowering the lives ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, ... clients already in the state and in nearby New Hampshire, Massachusetts and Canada, ...
(Date:2/23/2017)... ... , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located ... 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier this ... and dentists who have earned high ratings and superior patient reviews from multiple credible ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... announced today that it will soon begin franchising throughout the U.S. starting this ... to help bring the practice of meditation mainstream. Current Meditation will be the ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
(Date:2/23/2017)... ... ... Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical ... Autism, is now enrolling at three new sites. These new sites are in addition ... “There are currently no approved drugs that address the core symptoms of autism,” said ...
Breaking Medicine News(10 mins):